

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

CORRECTIVE ASSIGNMENT

NATURE OF CONVEYANCE:

Corrective Assignment to correct the name of the assignor from 'EPITECH SA' to --EPISOURCE SA--. previously recorded on Reel 016862 Frame 0490. Assignor(s) hereby confirms the entire right, title and interest for the United States and in all countries..

CONVEYING PARTY DATA

Name	Execution Date
EPISOURCE SA	12/15/2004

RECEIVING PARTY DATA

Name:	DFB PHARMACEUTICALS, INC.
Street Address:	3909 Hulen Street
City:	Fort Worth
State/Country:	TEXAS
Postal Code:	76107

PROPERTY NUMBERS Total: 7

Property Type	Number
Application Number:	10655435
Patent Number:	6548058
Patent Number:	6730513
Patent Number:	7014849
Patent Number:	7144729
Patent Number:	5968546
Patent Number:	6673603

CORRESPONDENCE DATA

Fax Number: (512)536-4598

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 512-536-3035

Email: jbyron@fulbright.com

Correspondent Name: Mark B. Wilson

Address Line 1: 600 Congress Ave.

PATENT

500359505

REEL: 019864 FRAME: 0180

OP \$280.00 10655435

Address Line 2:	Suite 2400
Address Line 4:	Austin, TEXAS 78701

ATTORNEY DOCKET NUMBER:	DFBP
-------------------------	------

NAME OF SUBMITTER:	Mark B. Wilson
--------------------	----------------

Total Attachments: 8  
source=DFBP#page1.tif  
source=DFBP#page2.tif  
source=DFBP#page3.tif  
source=DFBP#page4.tif  
source=DFBP#page5.tif  
source=DFBP#page6.tif  
source=DFBP#page7.tif  
source=DFBP#page8.tif

Express Mail Label No.: EV475167504US  
Date of Deposit: February 16, 2005

Attorney Docket No.: 17811-999

## ASSIGNMENT

**EpiSource SA**, a corporation organized under the laws of **Switzerland**, having principal offices at 1 Rue de Sébeillon, 1004 Lausanne, **Switzerland** ("the ASSIGNOR"), the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assigns, sells and transfers to **DFB Pharmaceuticals, Inc.**, a corporation organized under the laws of **Texas**, having principal offices at 3909 Hulen Street, Fort Worth, Texas 76107, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEE: (1) the entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patents and applications for patents as listed in Schedule A, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in the name of EpiSource SA at the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patents which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

EpiSource SA hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by EpiSource SA had this assignment, sale and transfer not been made.

EpiSource SA agrees, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.


EpiSource SA further agrees at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

EpiSource SA hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.


EpiSource SA further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

**For EpiSource SA:**

Date: December 15, 2004


  
Signature of:  
Title: Director  
EpiSource SA

IN WITNESS WHEREOF,

  
Signature of witness:

this 15<sup>th</sup> day of December 2004  
Date of signing

IN WITNESS WHEREOF,

  
Signature of witness:

this 15<sup>th</sup> day of DECEMBER, 2004  
Date of signing

**For DFB Pharmaceuticals, Inc.:**

Date:

Brook Shust.

Signature of:

Title: Chief Scientific Officer  
DFB Pharmaceuticals, Inc.

IN WITNESS WHEREOF,

Nab Singh  
Signature of witness:

this 15<sup>th</sup> day of December 2004.  
Date of signing

IN WITNESS WHEREOF,

[Signature]  
Signature of witness:

this 15<sup>th</sup> day of December 2004.  
Date of signing

**SCHEDULE A**

1. 17811-014-004 (M-14 AU)  
Australian Patent Application No. 60098/00  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
2. 17811-014-008 (M-14 CA)  
Canadian Patent Application No. 2,379,949  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
3. 17811-014-019 (M-14 EP)  
European Patent Application No. 00946228.4  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
4. 17811-014-032 (M-14 JP)  
Japanese Patent Application No. 2001-511156  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
5. 17811-014-061 (M-14 WO)  
PCT Patent Application No. PCT/IB00/01076  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
6. 17811-014 (M-14)  
United States Patent No. 6,548,058  
Entitled: "Keratinocyte Culture and Uses Thereof"
7. 17811-014 CIP (M-14 CIP)  
United States Patent No. 6,730,513  
Entitled: "Keratinocyte Culture and Uses Thereof"

8. 17811-014 NATL (M-14 NATL)  
United States Patent Application No. 10/031,188  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
9. 17811-015 (M-15)  
United States Patent No. 5,968,546  
Entitled: "Keratinocyte Culture from Precursor Cells"
10. 17811-017 (M-17)  
United States Patent No. 6,673,603  
Entitled: "Cell Paste Comprising Keratinocytes and Fibroblasts"
11. 17811-017 CIP (M-17 CIP)  
United States Patent Application No. 10/324,257  
Entitled: "Methods and Compositions for Tissue Regeneration"
12. 17811-017-032 CIP (M-17 CIP JP)  
Japanese Patent Application No. 2003-157362  
Entitled: "Methods and Compositions for Tissue Regeneration"
13. 17811-017-061 CIP (M-17 CIP WO)  
PCT Patent Application No. PCT/US03/27888  
Entitled: "Methods and Compositions for Tissue Regeneration"
14. 17811-017-004 (M-17 AU)  
Australian Patent Application No. 2001286952  
Entitled: "Methods and Compositions for Tissue Regeneration"
15. 17811-017-008 (M-17 CA)  
Canadian Patent Application No. 2426107  
Entitled: "Methods and Compositions for Tissue Regeneration"

16. 17811-017-019 (M-17 EP)  
European Patent Application No. 01966441.6  
Entitled: "Methods and Compositions for Tissue Regeneration"
17. 17811-017-061 (M-17 WO)  
PCT Patent Application No. PCT/US01/27104  
Entitled: "Methods and Compositions for Tissue Regeneration"
18. 17811-028 (M-28)  
United States Patent Application No. 10/655,435  
Entitled: "Fibrin Cell Supports and Methods of Use Thereof"
19. 17811-028-061 (M-28 WO)  
PCT Patent Application No. PCT/IB03/04506  
Entitled: "Fibrin Cell Supports and Methods of Use Thereof"

Express Mail Label No. EV475167504US

Date Deposited: February 16, 2005

08-11-2005

Attorney Docket No. 17811-915

FORM PTO-1595  
(Rev. 6-93)  
OMB No. 0651-0011 (exp. 4/94)



103059336

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Epitech SA (executed 12/15/04)

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies)

Name: DFB Pharmaceuticals, Inc.

Internal Address: 3909 Hulen Street  
Fort Worth, TX 76107

Street Address: (same as above)

3. Nature of conveyance:

☒ Assignment

☐ Security Agreement

☐ Merger

☐ Change of Name

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is \_\_\_\_\_

A. Patent Application No(s):

SEE ATTACHED SCHEDULE A

B. Patent No(s):

SEE ATTACHED SCHEDULE A

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence  
Concerning document should be mailed:

Name: Ivor R. Elrifi, Ph.D.  
Address: MINTZ, LEVIN, COHN, FERRIS  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, MA 02111

6. Total number of applications and patents involved: 13 7

7. Total fee (37 CFR 3.41)

\$280.00

☒ Enclosed

☒ The Commissioner is authorized to charge Deposit Account  
No: 50-0311, Reference No. 17811-915.

DO NOT USE THIS SPACE

9. Statement and signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Christina K. Stock Reg. No. 45,889

Name of Person Signing

*Christina K. Stock*

Signature

2/16/2005

February 16, 2005

Total number of pages including cover sheet, attachments, and document: [8]

Mail documents to be recorded with required cover sheet information to:

MAIL STOP ASSIGNMENT RECORDATION SERVICES

Director of the U.S. Patent and Trademark Office

P.O. Box 1450, Alexandria, VA 22313-1450

TRA 2007257v1

03/02/2005 08:01:00 00000129 500311 6548058  
01 FC:0021 960.00 BA 280.00 OP

RECORDED: 09/21/2007

PATENT  
REEL: 019864 FRAME: 0189